Differentiation of Human Embryonic Stem Cells into Dopaminergic Nerve Cells


The invention described here is a novel method of differentiating human embryonic stem cells (hESCs) into dopaminergic nerve cells, which is preferable to the currently available dopaminergic differentiation techniques.

This invention potentially provides a source of sufficient dopaminergic cells not only for the clinical transplantation of dopaminergic tissue but also for in vitro studies of human cells useful for pharmaceutical screens related to neurodegenerative disorders and substance abuse.

Neurodegenerative disorders encompass a range of debilitating conditions including Parkinson's disease, Alzheimer's disease, and Huntington's disease. The primary cause of cognitive dysfunction for these three disorders has been directly linked to neuron degeneration, usually in specific areas of the brain. Transplantation of fetal dopaminergic neurons in affected areas of the brain in late stage Parkinson's disease has demonstrated clinical utility in human patients. However, fetal transplantation therapy generally requires human tissue from at least 3-5 embryos to obtain a clinically reliable improvement in the patient, thus demonstrating a need for a larger and more reliable source of dopaminergic cells. HESCs are a promising alternative source of cells because they can grow in culture indefinitely and have the ability to differentiate into a variety of cell types. One of the most efficient methods for conversion of hESCs to dopaminergic neurons requires the presence of mouse stromal cells which have an undefined dopaminergic inducing activity. However, the major disadvantage of this method is the exposure of hESC to mouse cells, which hinders any downstream clinical application due to possible transfer of animal cells and pathogens. This invention has unveiled the molecular nature of the activity of the mouse cells and established an efficient alternative approach for dopamine neuron generation, which is more suitable for clinical application. This innovative approach potentially provides a large and reliable source of dopaminergic cells sufficient for clinically relevant transplantation of dopaminergic tissue as well as in vitro pharmacologic studies of human dopaminergic cells.

Potential Commercial Applications: Competitive Advantages:
  • Human dopaminergic cell source for neuronal transplantation, with potential clinical application to Parkinson's disease and possibly other neurodegenerative disorders.
  • Human dopaminergic cell source for in vitro models for pharmaceutical screens relevant to neurodegenerative disorders and substance abuse.
 


Development Stage:
Early-stage

Inventors:

William Freed (NIDA)  ➽ more inventions...

Tandis Vazin (NIDA)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,628,962 issued 2014-01-14
PCT Application No. PCT/US2009/065007
US Application No. 13/129,661

Licensing Contact:
Vio Conley, M.S.
Email: conleyv@mail.nih.gov
Phone: 240-276-5530

OTT Reference No: E-176-2008/0
Updated: Oct 11, 2017